New hope for tough leukemia cases? DFP-10917 trial targets relapsed AML
Disease control
Terminated
This study tested a new drug called DFP-10917 in 167 adults with acute myeloid leukemia (AML) that had returned or not responded after 2 to 4 prior treatments. Participants received either DFP-10917 or one of several standard reinduction therapies. The goal was to see if DFP-1091…
Phase: PHASE3 • Sponsor: Delta-Fly Pharma, Inc. • Aim: Disease control
Last updated May 01, 2026 16:01 UTC